DealsMay 7, 2026, 08:21 AM
Oragenics to License CardioDialysis for TBI Treatment
AI Summary
Oragenics, Inc. announced signing a Letter of Intent (LOI) with Sigyn Therapeutics, Inc. to exclusively license CardioDialysis™, an extracorporeal blood purification technology. This technology targets TBI-induced systemic inflammation by clearing inflammatory and pathogenic molecules from the bloodstream. The proposed license agreement aims to position Oragenics with a dual-modality strategy, combining CardioDialysis™ with its existing ONP-002 to address TBI inflammation both inside and outside the brain.
Key Highlights
- Oragenics signed an LOI to exclusively license CardioDialysis™ from Sigyn Therapeutics.
- CardioDialysis™ is a blood purification technology for TBI and neurodegenerative diseases.
- It targets TBI-induced systemic inflammation, complementing Oragenics' ONP-002.
- Oragenics expects to issue 3,250,000 shares of restricted preferred stock to Sigyn.
- A 3% royalty on revenue from sales of the licensed technology is expected for six years.
- The proposed license agreement is targeted to close within 90 days.